Thomas Sandal is a biotech leader with 30+ years of experience, specializes in early-stage discovery and CMC development of antibodies and fragments for various indications like RA, ALI, Psoriasis, oncology, and microbiome products. He has held executive positions at PokeAcell, AGC Biologics, Microbiotica Ltd, Crescendo Biologics Ltd, GSK Ltd, and Domantis, advancing numerous compounds to clinical stages. Thomas, a molecular biologist with an engineering degree from the Technical University of Denmark and a Business Administration degree from Copenhagen University College of Engineering, excels in biotech company building and R&D strategy.